Komodo Health Introduces the First Integrated Patient Insurance Dataset to Enhance Patient-Level Insights for Life Sciences

Komodo Sets a New Industry Standard for Applying Real-World Data and Analytics to More Accurately Understand Patient Insurance Status at Both Regional and National LevelsSAN FRANCISCO--(BUSINESS WIRE)

BusinesswireJun 12 08:00 ET

H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $100

H.C. Wainwright analyst Ram Selvaraju maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success r

moomoo NewsJun 11 06:32 ET · Ratings

BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $71

BTIG analyst Julian Harrison maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and maintains the target price at $71.According to TipRanks data, the analyst has a success rate of 49.

moomoo NewsJun 10 21:31 ET · Ratings

Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $66

Needham analyst Serge Belanger maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and maintains the target price at $66.According to TipRanks data, the analyst has a success rate of 4

moomoo NewsJun 10 14:32 ET · Ratings

MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham

MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham

Dow JonesJun 10 13:58 ET

Express News | Needham Reiterates Buy on MoonLake, Maintains $66 Price Target

BenzingaJun 10 13:49 ET